Neurofibromatosis Therapeutics Program: Program Development, Tumor Treatment, and Side Effect Management (215)The advanced practice provider is instrumental in designing, developing, and growing a program to treat tumors associated with Neurofibromatosis (NF) Type 1 and 2. Both NF1 and NF2 are autosomal dominant genetic disorders associated with the growth of both benign and malignant tumors of the peripheral and central nervous system. In the last two years selumetinib, a MEK inhibitor, gained FDA approval for treatment of plexiform neurofibromas in the children with NF. Read more...
- Molly Hemenway DNP MS RN CPNP-AC/PC
- CNE Hours